Multiplexed FRET-FLIM Profiling of Immune Checkpoint Interactions Predicts Response to Atezolizumab in Urothelial Carcinoma
Camacho, L.; Cacho-Navas, C.; Agüero, J.; Batmunkh, B.; Gracia, J. M.; O Sullivan, K.; Rementeria, M.; Miles, J.; Gumuzio, J.; Aguirre, F.; Martin Algarra, S.; de Andrea, C. E.; Parker, P. J.; Calleja, V.
Show abstract
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown great promise in treating bladder cancer and are now part of the standard treatment for advanced disease. However, many patients still fail to respond to treatment and at present many biomarkers are assessed but have yet shown only limited results. Therefore, with the advent of combination treatments and the increase of immune related adverse event, the search for reliable predictive biomarkers is paramount. Using a multiplexed enhanced FRET-FLIM based technique (QF-Pro) we quantified the interaction of PD-1/PD-L1, CTLA-4/CD80 and TIGIT/CD155 immune checkpoints in a pre-treatment TMA of 46 patients treated with atezolizumab. The association between higher PD-1/PD-L1 ICP interaction state and treatment efficacy was demonstrated in the male sample cohort, where it identified patients with better PFS. Conversely, patients exhibiting higher CTLA-4/CD80 engagement had a worse response to atezolizumab. Remarkably, the dual assessment of patients with high PD-1/PD-L1 and low CTLA-4/CD80 allowed to identify the best responders. These results indicate that the monitoring of patients immune profile in urothelial carcinoma might be critical in identifying patients who may benefit from combination therapy.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases 90%
- Intracellular Optical Doppler Phenotypes of Chemosensitivity in Human Epithelial Ovarian Cancer 90%
- Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma 90%
Similar papers in this journal
- CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients 92%
- Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy 90%
- Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy 90%
Similar papers in this journal
- Data independent acquisition mass spectrometry (DIA-MS) analysis of FFPE rectal cancer samples offers in depth proteomics characterization of response to neoadjuvant chemoradiotherapy 90%
- Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer 89%
- A microscale platform for the comprehensive analysis of bacterial translation initiation 89%
Similar papers in this journal
- Use of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinoma 92%
- An AI-powered blood test to detect cancer using nanoDSF 91%
- Protein profiling of breast carcinomas reveals expression of immune-suppressive factors and signatures relevant to patient outcome 90%
Similar papers in this journal
- Frequent post-treatment monitoring of colorectal cancer using individualized ctDNA validated by multi-regional molecular profiling 91%
- Non-B DNA-Informed Mutation Burden as a Marker of Treatment Response and Outcome in Cancer 90%
- A prospective validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.